Veru Inc. (NASDAQ:VERU) Receives Average Rating of “Moderate Buy” from Brokerages

Veru Inc. (NASDAQ:VERU) has been given a consensus rating of “Moderate Buy” by the five ratings firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $25.00.

Several brokerages recently commented on VERU. Oppenheimer reissued an “outperform” rating on shares of Veru in a research note on Thursday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Veru in a report on Wednesday, October 8th. Wall Street Zen raised shares of Veru from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Canaccord Genuity Group started coverage on Veru in a research note on Thursday. They issued a “buy” rating and a $25.00 price target on the stock.

Institutional Investors Weigh In On Veru

Institutional investors and hedge funds have recently modified their holdings of the business. Jacobs Levy Equity Management Inc. bought a new stake in shares of Veru in the third quarter worth about $110,000. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Veru in the 3rd quarter valued at approximately $38,000. Choreo LLC bought a new position in shares of Veru in the 3rd quarter valued at about $287,000. Cassaday & Co Wealth Management LLC bought a new position in Veru during the third quarter worth about $47,000. Finally, GSA Capital Partners LLP acquired a new position in shares of Veru during the 3rd quarter worth approximately $616,000. 47.16% of the stock is owned by institutional investors.

Veru Trading Up 2.7%

VERU stock opened at $2.32 on Friday. Veru has a one year low of $2.11 and a one year high of $14.20. The firm has a 50-day moving average of $2.89 and a two-hundred day moving average of $4.09. The firm has a market capitalization of $37.24 million, a PE ratio of -1.05 and a beta of -1.01.

Veru Company Profile

Veru Inc is a clinical-stage biopharmaceutical company headquartered in Miami, Florida. The company is dedicated to the development and commercialization of novel therapies in the fields of oncology and infectious disease. Veru’s research strategy centers on advancing small-molecule and biologic candidates through clinical trials, leveraging its in-house manufacturing and formulation capabilities as well as strategic partnerships to support late-stage development.

The company’s lead product candidate is sabizabulin (VERU-111), an oral, microtubule-disrupting agent undergoing pivotal trials for indications that include metastatic castration-resistant prostate cancer and hospitalized patients with severe COVID-19.